TY - JOUR
T1 - Pleiotropic effects of DCLK1 in cancer and cancer stem cells
AU - Chhetri, Dibyashree
AU - Vengadassalapathy, Srinivasan
AU - Venkadassalapathy, Santhosh
AU - Balachandran, Varadharaju
AU - Umapathy, Vidhya Rekha
AU - Veeraraghavan, Vishnu Priya
AU - Jayaraman, Selvaraj
AU - Patil, Shankargouda
AU - Iyaswamy, Ashok
AU - Palaniyandi, Kanagaraj
AU - Gnanasampanthapandian, Dhanavathy
N1 - Publisher Copyright:
© 2022 Chhetri, Vengadassalapathy, Venkadassalapathy, Balachandran, Umapathy, Veeraraghavan, Jayaraman, Patil, Iyaswamy, Palaniyandi and Gnanasampanthapandian.
PY - 2022/9/26
Y1 - 2022/9/26
N2 - Doublecortin-like kinase 1 (DCLK1), a protein molecule, has been identified as a tumor stem cell marker in the cancer cells of gastrointestinal, pancreas, and human colon. DCLK1 expression in cancers, such as breast carcinoma, lung carcinoma, hepatic cell carcinoma, tuft cells, and human cholangiocarcinoma, has shown a way to target the DCLK1 gene and downregulate its expression. Several studies have discussed the inhibition of tumor cell proliferation along with neoplastic cell arrest when the DCLK1 gene, which is expressed in both cancer and normal cells, was targeted successfully. In addition, previous studies have shown that DCLK1 plays a vital role in various cancer metastases. The correlation of DCLK1 with numerous stem cell receptors, signaling pathways, and genes suggests its direct or an indirect role in promoting tumorigenesis. Moreover, the impact of DCLK1 was found to be related to the functioning of an oncogene. The downregulation of DCLK1 expression by using targeted strategies, such as embracing the use of siRNA, miRNA, CRISPR/Cas9 technology, nanomolecules, specific monoclonal antibodies, and silencing the pathways regulated by DCLK1, has shown promising results in both in vitro and in vivo studies on gastrointestinal (GI) cancers. In this review, we will discuss about the present understanding of DCLK1 and its role in the progression of GI cancer and metastasis.
AB - Doublecortin-like kinase 1 (DCLK1), a protein molecule, has been identified as a tumor stem cell marker in the cancer cells of gastrointestinal, pancreas, and human colon. DCLK1 expression in cancers, such as breast carcinoma, lung carcinoma, hepatic cell carcinoma, tuft cells, and human cholangiocarcinoma, has shown a way to target the DCLK1 gene and downregulate its expression. Several studies have discussed the inhibition of tumor cell proliferation along with neoplastic cell arrest when the DCLK1 gene, which is expressed in both cancer and normal cells, was targeted successfully. In addition, previous studies have shown that DCLK1 plays a vital role in various cancer metastases. The correlation of DCLK1 with numerous stem cell receptors, signaling pathways, and genes suggests its direct or an indirect role in promoting tumorigenesis. Moreover, the impact of DCLK1 was found to be related to the functioning of an oncogene. The downregulation of DCLK1 expression by using targeted strategies, such as embracing the use of siRNA, miRNA, CRISPR/Cas9 technology, nanomolecules, specific monoclonal antibodies, and silencing the pathways regulated by DCLK1, has shown promising results in both in vitro and in vivo studies on gastrointestinal (GI) cancers. In this review, we will discuss about the present understanding of DCLK1 and its role in the progression of GI cancer and metastasis.
KW - cancer stem cells
KW - CRISPR/Cas9
KW - DCLK1
KW - intestinal neoplasia
KW - miRNA
KW - siRNA
UR - http://www.scopus.com/inward/record.url?scp=85139903540&partnerID=8YFLogxK
U2 - 10.3389/fmolb.2022.965730
DO - 10.3389/fmolb.2022.965730
M3 - Review article
AN - SCOPUS:85139903540
SN - 2296-889X
VL - 9
JO - Frontiers in Molecular Biosciences
JF - Frontiers in Molecular Biosciences
M1 - 965730
ER -
